Overview
Updated 14 Jul 2026
Paul G. Richardson, MD, is Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute (Harvard Medical School affiliate). The public record shows 2,062 publications with 132,822 citations (h-index 172), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2005–2007).
- Most recent indexed publication: 2026 · European journal of haematology
- Top research focus: Multiple Myeloma Research and Treatments
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 83 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 886.
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Sponsor: Oncopeptides AB
InvestigatorPhase 1/PHASE2TerminatedNCT01897714 - Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Sponsor: Prolexys Pharmaceuticals
InvestigatorPhase 1/PHASE2UnknownNCT01695590 - Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
InvestigatorPhase 1/PHASE2CompletedNCT01615029
Industry payments
Updated 14 Jul 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments$30,710openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20258 payments$16,848openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20256 payments$13,668openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2005–2007 per NIH RePORTER. The latest:
- defibrotide for the treatment of severe hepatic veno-cc*
Dana-Farber Cancer Inst
FY2007$366,742R01FD002548 - Defibrotide for the treatment of severe hepatic veno-cc*
Dana-Farber Cancer Institute
FY2005R01FD002548
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Expert opinion on biological therapy
2026 - Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
American journal of hematology
2025 - Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Expert opinion on emerging drugs
2025
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc2,847 citations2011
- 04A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 05International uniform response criteria for multiple myeloma2,640 citations2006
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- MD
Medical College of St. Bartholomew's Hospital, University of London (UK)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →managingmyeloma.com ↗
Editorial & leadership rolesjournal and society appointments
- Chair (2011-2021, then emeritus Chair to 2023)
Multiple Myeloma Committee, Alliance for Clinical Trials in Oncology
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hms.harvard.edu ↗
Awards & honorshonors on the public record
- Joseph Michaeli Award for Outstanding Contributions to Myeloma
Lymphoma Leukemia & Myeloma Congress
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - Joseph Michaeli Award for Outstanding Contributions to Myeloma
Lymphoma Leukemia & Myeloma Congress
2025 - James Griffin Team Science Award
Dana-Farber (2023), co-recipient as part of the Multiple Myeloma clinical research group, inaugural award
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliationsappointments beyond the home institution
- Brigham and Women's Hospital
Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hms.harvard.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomacrowd.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Other
dana-farber.org/find-a-doctor/paul-g-richardson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Other
myeloma.org/videos/ash-2016-multiple-myeloma-overview-dr-paul-richardson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗ - X / Twitter
x.com/DanaFarber/status/1978502379562483805
Mentions by otherswhere others cite or feature them
- X / Twitter
Dana-Farber (official @DanaFarber X account) congratulating Paul Richardson, MD on the Joseph Michaeli Award
- X / Twitter
Lymphoma, Leukemia & Myeloma Congress (@llmcongress X account) announcing Richardson's keynote and Michaeli Award
- LinkedIn
Dana-Farber LinkedIn post referencing IMF naming Dr. Richardson for the Kyle Lifetime Achievement Award
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Steven Greenberg, MD
Harvard University
- 954
- publications
- 144
- h-index
- 9
- trials
David Scadden, MD
Harvard University
- 665
- publications
- 124
- h-index
- 4
- trials
David Reardon, MD
Harvard University
- 1,226
- publications
- 121
- h-index
- 28
- trials